Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Abraxane Reps Will Number 100: Approval Of Novel Paclitaxel Formulation Expected In Third Quarter

This article was originally published in The Pink Sheet Daily

Executive Summary

American Pharmaceutical Partners hopes to position metastatic breast cancer drug as superior to Taxol in safety, convenience and effectiveness. Parent company American Bioscience filed the NDA in early March and expects a priority review.

You may also be interested in...



Abraxane Cost-Benefit Data Could Support Price Premium Over Taxol, Taxotere

American Pharmaceutical Partners plans to begin shipping Abraxane (nanoparticle albumin-bound paclitaxel) within 45 days. Based on data presented at the American Society of Clinical Oncology meeting, Abraxane demonstrated a cost-benefit to Bristol's Taxol and Aventis' Taxotere for treatment of breast cancer.

Abraxane Cost-Benefit Data Could Support Price Premium Over Taxol, Taxotere

American Pharmaceutical Partners plans to begin shipping Abraxane (nanoparticle albumin-bound paclitaxel) within 45 days. Based on data presented at the American Society of Clinical Oncology meeting, Abraxane demonstrated a cost-benefit to Bristol's Taxol and Aventis' Taxotere for treatment of breast cancer.

FDA Approves APP's Abraxane Paclitaxel Formulation

American Pharmaceutical Partners will submit survival data and pharmacokinetic data in subjects with hepatic impairment for Abraxane as part of the company's Phase IV commitments. APP hopes to position Abraxane as safer and more effective than Bristol's Taxol and paclitaxel generics.

Topics

UsernamePublicRestriction

Register

LL1133951

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel